Research Article
Current Status of Metabolic Compliance and Risk of Cardiovascular Disease in Patients with Type 2 Diabetes in the Zhuang Population in China
Table 2
Analysis of current drug treatment of patients with abnormal metabolic indicators (blood glucose, blood pressure, and blood lipid).
| | Group | Characteristics | CVD | Non-CVD | | n (%) | Abnormality of blood glucose, blood pressure and blood lipid medication n (%) | n (%) | Abnormality of blood glucose, blood pressure and blood lipid medication n (%) |
| | Abnormal blood glucose | | 138 (85.71) | 107 (77.54) | 1651 (90.01) | 1312 (79.47) | | OHD only | 37 (26.81) | 485 (29.38) | | Insulin only | 53 (38.41) | 628 (38.04) | | OHD + insulin | 17 (12.32) | 199 (12.05) |
| | Abnormal blood pressure | | 126 (78.26) | 4 (3.17) | 946 (52.15) | 86 (4.74) | | ACEI/ARB | | 1 (0.08) | | 3 (0.32) | | Calcium channel | | 3 (2.38) | | 78 (8.25) | | β-blockers | | 0 (0.0) | | 5 (0.53) |
| | Dyslipidemia | | 146 (90.68) | 6 (4.11) | 1244 (68.58) | 59 (4.74) | | Statins | 6 (4.11) | 59 (4.74) |
|
|
Notes. OHD: oral hypoglycemic drug; ACEI: ACE inhibitor; ARB: A II receptor antagonist.
|
